ProCE Banner Activity

ARCHER 1050: First-line Dacomitinib vs Gefitinib in EGFR-Mutant Advanced NSCLC

Slideset Download
Conference Coverage
In this phase III study, dacomitinib demonstrated superior PFS and DoR, but with increased toxicity, vs gefitinib in treatment-naive patients with advanced NSCLC and EGFR-activating mutations.

Released: June 09, 2017

Expiration: June 08, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology